Tag: CBT > DEA Scheduling: Page 8

Interviews & Opinion

Opinion: Rescheduling Is Recriminalizing, Descheduling Is Decriminalizing

President of cannabis genetics company DNA Genetics, Rezwan Khan, weighs in on Biden's cannabis policy reform plan and how rescheduling or descheduling the plant would impact the industry.

August 29, 2023

Hemp Regulations in U.S.

DEA May Propose Regulations That Would Threaten the Hemp-Derived Cannabinoid Industry and Cast a Dark Cloud Over CBD Industry

The federal agency announced in early May that it plans to soon propose new rules that would classify synthetically derived cannabinoids as controlled substances and would decontrol CBD up to 0.1% THC on a weight-to-weight or weight-to-volume basis.

May 26, 2023

The Last Word

A Unified National Cannabis Policy

FDA’s new senior public health adviser Norman Birenbaum talks about the agency’s approach to hemp-derived products and cannabis regulation, and what may come next.

March 13, 2023

Hemp Research

Risky Research

January 5, 2023

2022 Election and Cannabis

Will Cannabis Policy Change?

Past reviews of cannabis’s Schedule I classification in the Controlled Substances Act—the most recent of which took five years and ended in 2016—have never moved the needle with the Drug Enforcement Agency. Many wonder if this time will be different with the directive coming from the president.

October 26, 2022

Legislation and Regulation

Biden's Order to Review Cannabis 'Truly Historic,' But What's at Stake?

Many industry experts agree removing cannabis from the list of Controlled Substances would be ideal. But a rescheduling could make things more complex—or even a 'disaster' for the state-legal industry.

October 26, 2022